Can Adjusted LegoChem Bio Take Off Again?

[Asia Economy Reporter Jang Hyowon] LegoChem Biosciences, which recently showed a correction trend, is expected to rise again as the momentum for technology exports is highlighted.

On the 5th, Ha Taegi, a researcher at Sangsangin Securities, pointed out in a report, "LegoChem Biosciences' stock price has been adjusted downward due to the resumption of short selling, the overall weakness of bio stocks based on new drug development, and groundless rumors."

Researcher Ha said, "However, the new drug development schedule progressing this year is judged to be proceeding as originally planned, and the plans for 2 to 3 license-outs (L/O) are still valid," adding, "As time passes, the number of new drug pipelines will increase, and the corporate value is expected to increase as well."

The future stock price rise trigger for LegoChem Biosciences is expected to be the cumulative effect of license-outs anticipated in the second half of the year. Platform license-outs are likely to be mid-sized deals like last year, but if 2 to 3 accumulate, they can act as momentum for stock price increases.

Also, in the third to fourth quarter of this year, it will be important to confirm whether Fosun Pharma in China can verify positive safety and efficacy data from the breast cancer clinical phase 1a data. The value of the breast cancer pipeline will increase, and especially the value of LegoChem Biosciences' antibody-drug conjugate (ADC) platform and ADC pipeline will be highlighted, leading to a rise in stock price.

He stated, "LegoChem Biosciences' future is positively evaluated due to the competitiveness of the ADC link, which allows for various ADC new drug development strategies," and added, "The current stock price has been sufficiently adjusted and there seems to be no reason for further decline."

This content was produced with the assistance of AI translation services.